New Five-Year Data Support Superiority of Novartis Drug Tasigna® Over Gleevec® in Newly Diagnosed Ph+ CML Patients
New five-year data support superiority of Novartis drug Tasigna® over Gleevec® in newly diagnosed Ph+ CML patients
EAST HANOVER, N.J., Dec. 8, 2013 /PRNewswire/ — Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna® (nilotinib) compared to Gleevec® (imatinib mesylate) tablets* at achieving deeper molecular responses across various Philadelphia…
Methadone Side Effects – Yahoo News Search Results
Related Methadone Side Effects Information…